Focus on hepatocellular carcinoma  by Bruix, Jordi et al.
CANCER CELL : MARCH 2004 · VOL. 5 · COPYRIGHT © 2004 CELL PRESS 215
Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent neo-
plasm worldwide (>500,000 deaths/year), and in some areas of
the world it represents the primary cause of cancer-related
death (Parkin et al., 2001). Years ago, HCC was considered a
major health problem in Asia and Africa, with minor prevalence
in Europe or America. However, current data indicate that its
incidence is steadily increasing in the West (Parkin et al., 2001).
This has raised the attention paid to its molecular pathogenesis
and to aspects related to epidemiology and treatment. This
focus summarizes the established knowledge regarding these
issues and points out the most active areas of research where
strong data are eagerly awaited.
Epidemiology and risk factors
The incidence of HCC has a wide geographical variation due to
the large heterogeneity of the penetration of the risk factors
within the population (Llovet et al., 2003). Any agent leading to
chronic liver injury, and eventually cirrhosis, constitutes an
oncogenic agent. The most relevant are hepatitis B (HBV) and
hepatitis C (HCV) viruses and alcohol (Table 1). Other causes of
hepatocyte damage (iron or copper deposition, non-alcoholic
steatohepatitis, or primary biliary cirrhosis), are also risk fac-
tors, but their lower prevalence diminishes their overall impor-
tance (Llovet et al., 2003).
HBV infection is highly prevalent in undeveloped countries
and in some areas of Asia. There, the infection is acquired at
birth or early in life, resulting in a very high incidence of HCC in
children and adults (Parkin et al., 2001; Llovet et al., 2003).
Observational investigations have shown that age of infection,
male gender, and active liver damage associated with flares of
viral replication are the major characteristics leading to
increased HCC risk (Llovet et al., 2003; Evans et al., 2002;Yang
et al., 2002). Viral genotypes may play a role, although no
strong data are available. Associated alcohol consumption fur-
ther heightens the risk, which is also enhanced by Aflatoxin B1
(AFB1) intake. This substance is a mycotoxin produced by fungi
that contaminate food stored in humid conditions. AFB1 is the
most potent oncogenic agent for the liver, and some areas with
high HBV infection rate (Philippines, South East Asia) also pre-
sent a high rate of AFB1 contamination, resulting in the highest
HCC prevalence. In some instances, HCC may be related to
occult HBV infection that is not detectable by serum markers
and is only identified by studying HBV fragments using RT-PCR
in tissue samples (Pollicino et al., 2004).
HCV is a blood-transmitted agent and is the major risk fac-
tor in Europe, Japan, and America. It overlaps with alcohol
intake, which in some areas such as France is still the major
oncogenic agent. The rising incidence of HCC in developed
countries is likely due to the spread of HCV 20–40 years ago.
Since 1990, HCV has been detectable, and blood products are
screened. Thus, with proper conditions, transmission of HCV
and postprocedure hepatitis (mainly transfusion) has
decreased, which should lead to a decrease of HCC incidence.
While HBV-related HCC may develop in the absence of cirrho-
sis or extensive liver fibrosis, the appearance of HCC in patients
with chronic HCV infection is usually preceded by the establish-
ment of significant liver damage (Llovet et al., 2003).
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Table 1. Incidence of HCC according to geographical area and distribution of risk factors
Age-adjusted incidence rates Risk factors
Geographic area Male Female HCV HBV Alcohol Other
Europe 60%70% 10%15% 20% 10%
Western Europe 5.8 1.6
Southern 9.8 3.4
Northern 2.6 1.3
North America 50%60% 20% 20% 10%
Northern 4.1 1.6
Southern 4.8 3.6
Asia and Africa 20% 70% 10% Aflatoxin
Japan 70% 10%20% 10% 10%
Eastern Asia 35.4 12.6
South-Eastern Asia 18.3 5.7
Middle Africa 24.2 12.9
World 14.9 5.5
Modified from Llovet et al., 2003, with permission from Lancet.
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Prevention
As described above, chronic liver damage due to any agent
results in an increased HCC risk. Thus, the optimal preventive
strategy is to reduce viral transmission and alcoholism. HBV
spread can be controlled by vaccination, which, as shown in
Taiwan, reduces HBV penetration and HCC incidence (Chang
et al., 1997). Thus, this intervention should be implemented
worldwide and may turn HCC into the first cancer prevented
through vaccination. There is no vaccine for HCV, and preven-
tion of infection should come from proper health care condi-
tions. Finally, public health campaigns should focus on the risks
of excessive alcohol intake, as done for smoking.
If primary prevention has not been feasible or successful,
the health strategy should aim to eradicate the acquired risk fac-
tor, or at least diminish its capacity to induce liver damage and
cirrhosis. Antiviral therapy for HBV is available through several
agents, but, although viral replication may cease, the virus may
integrate in the hepatocyte genome and exert its oncogenicity
(Block et al., 2003). Treatment for HCV infection is more effec-
tive. The combination of interferon and ribavirin may clear the
virus, and thus prevent the long-lasting damage that precedes
HCC development (Fried et al., 2002). If cirrhosis is established,
there is no proof that any intervention is effective in preventing
HCC (Camma et al., 2001). Lowering viral load or alcohol intake
may reduce liver disease progression, but the impact in cancer
risk is not defined. In fact,  the molecular events leading to can-
cer and the insult/repair phenomena leading to cirrhosis might
be coincidental in time, but may not be the same.
Oncogenic mechanisms
The molecular events linked to the development and progres-
sion of HCC are not well known. Malignant hepatocytes are the
result of sequential changes accumulated in mature hepato-
cytes or can derive from stem cells. The most accepted hypoth-
esis (Buendia, 2000; Thorgeirsson and Grisham, 2002)
describes a step-by-step process in which external stimuli
induce genetic alterations in mature hepatocytes leading to cell
death, cellular proliferation, and the production of monoclonal
populations. These populations harbor dysplastic hepatocytes
that evolve to dysplastic nodules (Theise et al., 2002). High-
grade dysplastic nodules are considered truly preneoplastic
lesions, and may develop into malignant tumors in 30% of cases
over a period of 1–5 years (Borzio et al., 2003). Initially, the nod-
ules do not exhibit neovascularization. At a more advanced time
point, hepatocytes exhibit a malignant phenotype associated to
neovessel formation nourished by the hepatic artery. These
early well-differentiated tumors are highly proliferative and
become less differentiated when they reach 1–1.5 cm
(Nakashima et al., 2003). At this stage, angiogenesis, tissue
invasion, and metastasis occur in up to 25% of the cases. Later
on, the neoplastic cells become undifferentiated and are able to
invade vessels and spread outside the liver, characteristics that
define end-stage disease.
Several investigators have searched for a specific genetic
damage at different evolutionary stages (Buendia, 2000;
Thorgeirsson and Grisham, 2002) (Table 2). However, no
homogeneous pattern has been defined. Few alterations have
been characterized in preneoplastic lesions and early HCC.
Loss of heterozygosity at 1p (1p36-p34) and in M6F/IGF2R
are early events in hepatocarcinogenesis, along with telomere
shortening. More recently, some genes (SP70, Glypican-3) or
gene sets (Smith et al., 2003; Paradis et al., 2003) have been
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Figure 1. BCLC staging and treatment strategy for patients diagnosed with HCC
HCC, hepatocellular carcinoma; CLT, cadaveric liver transplantation; LDLT, live donor liver transplantation; PEI, percutaneous ethanol injection; RF, radiofre-
quency. Modified from Llovet et al., 2003, with permission from Lancet.
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proposed as early HCC markers, although these results need
further confirmation.
In advanced stages, allelic alterations involve all the chro-
mosomes, the most specific being found in chromosomes 1, 4,
8, 16, and 17, but with none of them affecting more than 60% of
cases. Few studies link genetic abnormalities with gene expres-
sion. Downregulation of p53 is present in 30%–40% of cases.
The G to T mutation at codon 249 of the p53 gene defines
genetic damage due to aflatoxin (Staib et al., 2003).
Recent studies have suggested that the pathway leading to
HCC may differ according to etiology. HBV-related HCC would
exhibit a more intense genetic instability with several chromo-
some changes. By contrast, non-HBV related HCC would pre-
sent less instability, but more frequently suffer β catenin
mutations and activation of the wnt signaling pathway with
development of large nondisseminated tumors (Hsu et al.,
2000; Laurent Puig et al., 2001). Lately, microarray investiga-
tions have allowed the identification of a large number of genes
with increased or reduced expression, but the meaning of these
findings is still unclear. In most cases, the genes are related to
cell cycle regulation, inflammation, apoptosis, and collagen
deposition. In fact, a myriad of investigations have described
overexpression or repression of genes involved in the above
mentioned processes and even linked some of them to progno-
sis and evolution after treatment. Particularly, some genes have
been related to tumor progression (p16, SOCS-1, PEG10) or
tumor dissemination and metastasis (nm23-H1, osteopontin,
ARHC [Rho C], KAI1, and MMP14). However, none of the find-
ings has turned into a well-established marker in clinical prac-
tice. Ongoing investigations joining tumors of different origin,
stage, and evolution should finally identify the most relevant
abnormalities and differentiate those that are the cause of the
tumor and its evolution from those that are the effect of the
ongoing changes.
Early detection, diagnosis confirmation, and staging
If prevention is not effective, the only strategy to decrease can-
cer-related mortality is early detection, allowing effective therapy.
HCC accomplishes the requirements to become the target of
surveillance: it is a frequent disease with relevant morbidity and
mortality that has a well-defined population at risk—patients with
chronic liver disease. This population can be screened by a sen-
sitive tool (ultrasonography [US]) that is easily acceptable, and
effective treatment options are available (Llovet et al., 2003).
There are no large randomized clinical trials (RCTs) compar-
ing surveillance versus no surveillance, but based on results from
cohort investigations, regular US examination has become a rou-
tine clinical practice in cirrhotics. Almost 50% of HCC detected
under surveillance are amenable to effective therapy that
improves their outcome, but the main concern is the cost-effec-
tiveness of this intervention. If applied to all individuals with chron-
ic liver disease, the cost per year of life saved will largely exceed
the conventional $50,000 USD cutoff (Bolondi et al., 2001).Thus,
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Table 2. Chromosomal abnormalities in human HCC and genes affected
Numerical 
Chromosome aberrations Structural aberrations Loss of heterozygosity Genes involved
1 del 1p22, del 1p32-p36 1p, 1p35-36 L-myc
3 β catenin
4 − 4p, 4q, 4q32, 4q11-23 AFP/Alb/α-FGF
5 − t5;9 5p, 5q, 5q35-qter APC (5q21)
6 − del 6(q13-qter) 6q26-q27 M6P/IGF-IIR
7 + t17;7 (p13;p14)
8 − inv 8(q10) 8q c-myc (8q24)
9 − t5;9, inv 9(p12:q12) p16 INK4A & p19 ARF (9p21)
10 − 10q PTEN (10q23)
11 −,+ dup 11p15, del 11(p13-p14), 11p, 11p13-p15.1 WT-1, IGF-II, Cyclin D (11q13)
del 11p11, t11;22
12 −
13 −,+ 13q, 13q12, 13q12-q31 Rb-1 (13q-14)
15 −,+
16 − del 16q 16p, 16q22-24 Axin-1 (16p13.3), E cadherin (16q22.1),
SOCS-1 (16p13.13)
17 − t17;7 (p13;p14), t17;18(q25;q11), 17p, 17p13, 17p13-pter p53 (17p13)
t17;X, del 17(p12)
18 −,+ t17;18 (q25;q11) SMAD2, SMAD4 (18q21)
20 +
21 −,+
22 t22;? 22q, 22q11-12
X − t17:X
Table 3. Incidence of HCC according to risk factors and degree of liver
disease
HBV chronic infection Noncirrhotic HBV carriers : 0.4%0.6%/year
Cirrhotic patients: 2.6%6% /year
HCV chronic infection Noncirrhotic HCV individuals: <0.1%/year
Cirrhotic patients: 3%8%/year
Genetic hemochromatosis Cirrhosis: 5%/year
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surveillance has to be restricted to subjects at high risk that would
be potentially cured if diagnosed with HCC. Identification of high-
risk individuals is therefore a critical point.Table 3 depicts the inci-
dence of HCC in HBV and HCV infected subjects according to the
status of the liver. The risk is significant when cirrhosis is estab-
lished, whereas healthy carriers or patients with chronic hepatitis
exhibit a moderate risk that will never allow cost-effective surveil-
lance. HCC risk can also be stratified among cirrhotics. Male sex
and increased α-fetoprotein (AFP) concentration are the
strongest predictors. Other parameters such as dysplasia,
increased proliferation, or irregular regeneration need further val-
idation. Clearly, the major advancement will come from the identi-
fication of the genetic events that prompt the development of a
distinct hepatic nodule that ultimately will evolve into HCC. Most
HCC are initiated as a minute nodule in which cells strongly retain
the phenotype of benign hepatocytes. Dysplastic changes and
neoangionesis mark the transition to well-differentiated HCC and
overt malignancy.These events occur when the nodules measure
between 1 and 2 cm in diameter and herald the ability to prolifer-
ate, invade, and disseminate. At this stage, the tumors are easily
detected by imaging techniques (US, computed tomography,
magnetic resonance) that base their diagnostic capacity in the
recognition of an increased arterial vascularization (Burrel et al.,
2003).This allows for diagnosis without needing a positive biopsy
(Llovet et al., 2003), but at earlier stages, when vessel formation
is absent, biopsy is the sole diagnostic tool. Unfortunately, at early
stages, the cells retain their differentiation and biopsy is seldom
confirmatory. Accordingly, current research aims to identify the
molecular changes that govern transition along the depicted
phases and allow an accurate molecular diagnosis and definition
of the evolutionary stage. This will also depict the therapeutic tar-
gets to prevent the evolution into overt malignancy, and as a
whole, these data may ultimately establish a molecular classifica-
tion of HCC.
Treatment
The therapeutic strategy for HCC patients has to take into
account that in the vast majority of individuals, the tumor develops
in a diseased liver with a variable degree of function derange-
ment. Thereby, treatment should have a limited impact in liver
function. On the other hand, if the degree of liver function impair-
ment is severe, it will determine by itself a very dismal outcome of
the patient, irrespective of the treatment success, which would be
absolutely irrelevant. Figure 1 depicts the tumor staging and treat-
ment strategy that is currently applied in the Barcelona Clinic
Liver Cancer (BCLC) group. It links patient evaluation with treat-
ment indication, and thus is intended to guide clinical practice.
Unfortunately, as discussed above, there are no definitive molec-
ular tools to characterize the biology of HCC, and most treatment
decisions are still based on parameters such as size and tumor
number, as defined by imaging techniques.
Patients diagnosed at an early stage benefit from effective
treatments such as surgical resection, transplantation, or percu-
taneous ablation. Unfortunately, these benefit 30%–40% of the
patients currently evaluated in referral centers in the West, and
hence the vast majority are candidates to palliative treatments
that in most instances have never proven to have a positive
effect in survival (Llovet et al., 2003).
Surgical resection
Surgical resection is for most authors the first option in patients
with solitary tumors with well-preserved liver function and nor-
mal portal pressure. Patients fitting into this profile will tolerate
the resection of a hepatic segment, and their liver will not be
damaged by the cytokine release and ischemia reperfusion
injury related to surgery. Survival of optimal candidates may
exceed 60%–70% at 5 years, the main drawback being the high
rate of disease recurrence during followup (>50% at 3 years)
(Llovet et al., 2003). Recurrence might be due to tumor dissem-
ination or to de novo tumor formation. Presence of vascular
invasion or additional nodules are powerful predictors of recur-
rence related to dissemination, but future molecular analysis
should be able to give a more accurate prognosis than conven-
tional pathology. p53 protein dysfunction and reduced expres-
sion of p27 or nm23-H1, among others, have been related to
higher recurrence rate, but more data are needed prior to inte-
grating any gene signature into risk assessment. Acyclic
retinoids, interferon, adoptive immunotherapy, and internal radi-
ation may have some preventive effect, but their efficacy
requires extensive investigation (Llovet et al., 2003).
Liver transplantation
Liver transplantation is the treatment of choice for patients with
early HCC in decompensated cirrhosis. Patients with solitary
tumors ≤5cm or with up to 3 nodules ≤3 cm achieve outcomes
identical to patients transplanted because of end stage cirrhosis
without malignancy (70% at 5 years), and the recurrence rate is
less than with surgery (Llovet et al., 2003).This difference might
be used to support transplantation as the first therapeutic
option, but transplant has several drawbacks. The shortage of
donors prompts a waiting time between enlistment and trans-
plantation. During this time, the tumor may progress and
impede the procedure. Hence, the intention-to-treat survival is
significantly reduced. Live donation may partially ameliorate the
shortage of donors, but still we will have HCC patients waiting
for a liver during several months. Predictors of tumor progres-
sion are not available, and this is another field where molecular
profiling should provide major help. Graft rejection and viral rein-
fection are also major unsolved issues after transplant. HCV
reinfection of the graft is the rule, and at 5 years followup almost
50% of them will present with cirrhosis again (Prieto et al.,
1999). Development of better antiviral therapies and tools to
prevent collagen deposition are needed.
Percutaneous ablation
Percutaneous ablation is the third treatment option that may pro-
vide long-term cure. The most frequent techniques to ablate
tumors by physical means are ethanol injection and radiofrequen-
cy. Both are done under image guidance, and their maximal activ-
ity is achieved in nodules <3 cm, when complete response rates
account for 80% of cases (Llovet et al., 2003).The main drawback
is again the high rate of disease recurrence. If occurring in the sur-
roundings of the treated area, it reflects failure to provide adequate
local control.This lack of local control is not an issue with surgical
resection, which eliminates the tumor and the surrounding tissue,
containing the local tumor spread.Thus, percutaneous ablation is
an effective option, but is usually indicated if surgery is unfeasible.
Palliative therapy
Palliation aims to reduce symptoms related to cancer progression
and improve survival. Hence, only those treatments that have
consistently been shown to achieve this goal should be consid-
ered effective. Arterial chemoembolization and tamoxifen admin-
istration have undergone such robust investigation, but only the
former has proved survival benefits. Chemoembolization consists
of the selective injection of chemotherapy into the hepatic artery
followed by the obstruction of the vessels feeding the tumor. This
combined maneuver results in extensive tumor necrosis with
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slower tumor progression. However, during followup, the vascu-
larization is recovered, and despite repeated therapy, the neo-
plasm progresses and leads to death. Meta-analysis of all
published RCTs indicates that this option significantly improves
survival (Llovet et al., 2003). However, it benefits a narrow range
of nonsurgical patients who, being still asymptomatic, do not pre-
sent associated liver decompensation and/or invasion of the por-
tal vein or extrahepatic spread (30% of patients with nonsurgical
disease). Hence, those with slightly advanced liver disease pre-
senting symptoms, vascular invasion, or extrahepatic spread are
excluded, and there is no effective therapy for them. Tamoxifen
administration aiming to blockade estrogen receptors is ineffec-
tive, and the same stands for chemotherapy as the potential,
effects are prevented by the overexpression of the multidrug
resistance gene. Doxorubicin or cisplatinum have some marginal
activity, but lack any impact in survival (Llovet et al., 2003).
Radiation has antineoplastic capacity, but the hepatocytes are
also radiosensitive, and thus, extensive tumors can not be safely
treated. Immune control through activated lymphocytes is
explored by several groups, and the same applies for gene thera-
py that up to now is mostly restricted to laboratory animals.
Several biomodulators and new agents aiming to modulate cell
cycle, vessel formation, and matrix invasion are currently being
explored, but have not yet reached conventional clinical practice.
Conclusion
HCC is one of the major cancer killers that may benefit from
several health interventions and research actions. The identifi-
cation of the main risk factors allows the implementation of pri-
mary prevention, while the recognition of the population at risk
permits effective surveillance to achieve early detection and
effective therapy. Current investigations should define the
molecular pathways leading to cancer and define the targets for
new preventive and therapeutic strategies.
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